Key result
In hypertensive patients, a positive association was noted between BMI and the development of left ventricular hypertrophy (OR 1.39), and ACE inhibitors were found to be more effective in LVH regression compared to other agents.
Why the study?
What clinical factors and anti-hypertensive treatments influence the development and reversal of left ventricular hypertrophy in hypertensive patients?
Observational (n=50)
No
What clinical factors and anti-hypertensive treatments influence the development and reversal of left ventricular hypertrophy in hypertensive patients?
Effect estimate: OR 1.395 (95% CI 0.942-2.067)
p-value: p=0.096
In hypertensive patients, ACE inhibitors appear more effective than other agents for reversing LVH, and the presence of retinopathy suggests an increased chance of LVH regression with treatment.
Supports BMI-LVH link and possible ACE inhibitor advantage for regression; leaves open need for randomized confirmation.
INTRODUCTION: Left Ventricular Hypertrophy (LVH) often reflects as a physiological adaptation to chronic pressure overload. It has been identified as a strong independent risk factor of all-cause mortality and adverse cardiac events. Since not all subjects with hypertension develop LVH, understanding the clinical factors contributing to the development of LVH and the appropriate diagnostic and treatment strategies may help clinicians in conducting more definitive evaluation and managing the disease effectively. AIM: To assess the incidence of LVH in hypertensive subjects and the factors influencing its development and reversal. The study also evaluated the most effective diagnostic technique and therapy that could improve the disease symptoms and prognosis. MATERIALS AND METHODS: The prospective study, conducted at Jagadguru Sri Shivarathreeshwara (JSS) Medical College JSS University, Mysore, India, included 50 patients with hypertension. Detailed history of the recruited subjects was collected from patient records and through physical examination. Demographic and clinical characteristics such as age, gender, BMI, and stage of hypertension (stage I HTN and stage II HTN) were also obtained. Funduscopic examination was done for all patients for evidence of hypertensive retinopathy. Echocardiography (ECHO), electrocardiography (ECG), and chest X-Ray were used for detection of LVH. The patients were reviewed after six months and reassessment of LVH was carried out. Statistical analysis was conducted using SPSS software and R 3.2 package. RESULTS: Angiotensin-Converting Enzyme (ACE) inhibitors were found to be more effective in the treatment of LVH when compared to calcium channel blockers and beta blockers. ECHO was found to be the best method to diagnose LVH. In patients with stage I HTN, 47.1% had normal LVM. Around 53% of the subjects with stage I HTN and all with stage II HTN had abnormal LVM. Retinal changes were noted in 96.2% of abnormal LVM patients and 50% of normal LVM patients. A positive association between BMI and LVH (OR: 1.39) was also noted. CONCLUSION: BMI may positively influence LVH regression. The presence of retinopathy, in addition to LVH, suggests an increased chance of regression with anti-hypertensive treatment.
No takes yet. Share an insight, caveat, or question.
Prasanna Kumar Hassan Ramaswamy (2016) conducted an observational in Hypertension (n=50). Anti-hypertensive agents (ACE inhibitors, beta blockers, calcium channel blockers) was evaluated on Left Ventricular Hypertrophy (LVH) development associated with BMI (OR 1.395, 95% CI 0.942-2.067, p=0.096). In hypertensive patients, a positive association was noted between BMI and the development of left ventricular hypertrophy (OR 1.39), and ACE inhibitors were found to be more effective in LVH regression compared to other agents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: